Sintilimab and Bevacizumab Combined With Radiotherapy for Advanced Hepatocellular Carcinoma
The purpose of this study is to investigate both the efficacy and safety of sintilimab combined with bevacizumab and radiotherapy in advanced hepatocellular carcinoma.
Hepatocellular Carcinoma
DRUG: Sintilimab and Bevacizumab Combined with Radiotherapy
ORR (objective response rate), the proportion of patients who have a partial or complete response to therapy., through study completion, up to 2 year
PFS (progression-free survival), defined as the time from receiving treatment until disease progression or death from any cause, whichever happens first. Patients who withdraw or who are lost to follow-up will be censored at the date last known to be alive and progression free. Patients not having an event will be censored at the date last seen alive., through study completion, up to 2 year|OS (overall survival), defined as the time from receiving treatment until death from any cause. Patients who withdraw or who are lost to follow-up will be censored at the date last known to be alive. Patients remaining alive throughout the duration of the study will have their survival time censored on the date last seen alive., through study completion, up to 2 year|DCR (disease control rate), the proportion of patients whose tumors have shrunk or been stable for a certain period of time, including cases of complete response (CR), partial response (PR), or stable disease (SD)., through study completion, up to 2 year|LCR (local control rate), the percentage of lesions with absence of recurrence within the high-dose region （80% isodose volume）, through study completion, up to 2 year|Adverse effects, Adverse effects of sintilimab and bevacizumab combined with radiotherapy,number of participants with treatment-related adverse events as assessed by CTCAE v5.0, through study completion, up to 2 year
The purpose of this study is to investigate both the efficacy and safety of sintilimab combined with bevacizumab and radiotherapy in advanced hepatocellular carcinoma.